In this study, we revealed that miR-486-3p is a pivotal sorafenib resistance mediator by regulating FGFR4 and EGFR, and thus reverse HCC sorafenib resistance in vitro and in vivo. This evidence concerns the gene EGFR and hepatocellular carcinoma.